The presence of valine (V) at 
Introduction
Rituximab is a CD20-directed, IgG 1 -chimeric monoclonal antibody (mAb) used to treat patients with B-cell lymphomas, and various autoimmune disorders. Both quantitative as well as qualitative differences in NK-cell function may explain rituximab clinical activity. Higher circulating NK-cell levels and responses to rituximab have been reported in patients with indolent NHL suggesting that ADCC enacted by NK-cells may be a primary mechanism by which rituximab functions 1, 2 . Moreover, responses to rituximab may depend upon polymorphisms present in the FcγRIIIA (CD16) receptor, a receptor mainly expressed on NK-cells [3] [4] [5] .
Polymorphisms in position 48 and 158 of the FcγRIIIA receptor expression have been reported to influence human IgG 1 binding and ADCC activity [6] [7] [8] [9] . Polymorphisms at position 158 result in either valine (V) or phenylalanine (F) expression [6] [7] [8] [9] , the former of which is associated with increased depletion of peripheral blood B-cells 10 and response to rituximab in patients with indolent NHL 
Study Design

FcγRIIIa-158 Genotype Analysis
We analyzed the genotype of 52 unrelated, healthy individuals by sequencing exon 4 of FcγRIIIa gene. FcγRIIIa-158 polymorphisms were determined by allele-specific RT-PCR and directed sequencing of genomic DNA, as we previously described 5 . Genomic DNA was extracted from peripheral blood using a DNA isolation kit (Qiagen, CA, USA). The study was approved by the Dana Farber Cancer Institute's Institutional Review Board and written consent was obtained from each donor.
Cell Isolation and Culture
Peripheral blood mononuclear cells (PBMN) were isolated using Ficoll-Paque (Amersham, Uppsala, Sweden). NK-cells were selected from PBMN using the NK-cell isolation kit II (Miltenyi, Auburn CA) resulting in > 95% purity (CD3 -/CD56 + ). ARH-77
and Daudi cells were cultured as previously described. 
RT-PCR Analysis
Rituximab Binding to NK-cells
Rituximab (Genentech BioOncology, San Francisco, CA) binding was determined using an indirect method as previously described, 7 utilizing an anti-CD16 (3G8 clone) mAb.
NK-cells (2x10 5 ) were incubated with rituximab at concentrations of 10, 50, 100 and 200µg/ml for 30 min at 4°C, followed by incubation with anti-CD16 FITC and anti-CD56 PE mAbs at 4°C for 20 minutes. After incubation, NK-cells were washed with PBS and analyzed by flow cytometry. CD16 median fluorescence intensity (MFI) was determined 
Statistical Analysis
Differences among polymorphic groups were compared by the Kruskal-Wallis and
Mann-Whitney tests. The correlations between gene expression and CD16 receptors was assessed using the Pearson correlation coefficient.
Results and Discussion
We Figure 1A ).
This observation is particularly intriguing in view of the fact that the absolute number of
For personal use only. on October 28, 2017. by guest www.bloodjournal.org From CD16 receptors per NK-cell was significantly higher in donors who expressed at least one valine at FcγRIIIa-158 (i.e. were either V/V or V/F) versus F/F (p=0.029; Figure 1B ).
The basis for these discordant findings between FcγRIIIa transcript expression and cellsurface protein levels among individuals with FcγRIIIa-V/F remains to be clarified, but may reflect relative differences in transcript or protein stability, and/or recycling of CD16 at the cell surface imposed by the expression of valine.
We next evaluated the functional implications of FcγRIIIa-158 polymorphisms by studying rituximab binding and rituximab-dependent NK-cell-mediated cytotoxicity.
Both rituximab binding (Figure 2A , and suggest that the expression level of cell-surface CD16 may also contribute to augmented rituximab binding and ADCC activity, in addition to possible differences in binding affinity. 
